1h Free Analyst Time
P2X Purinoceptor 3 - Pipeline Review, H1 2020Speak directly to the analyst to clarify any post sales queries you may have.
Summary
According to the recently published report 'P2X Purinoceptor 3 - Pipeline Review, H1 2020'; P2X Purinoceptor 3 (P2RX3) pipeline Target constitutes close to 13 molecules. Out of which approximately 12 molecules are developed by companies and remaining by the universities/institutes.
P2X Purinoceptor 3 (P2RX3) - P2X purinoceptor 3 is a protein encoded by the P2RX3 gene. It belongs to the family of purinoceptors. This receptor functions as a ligand-gated ion channel and transduce ATP-evoked nociceptor activation. This receptor is important for peripheral pain responses, and also participates in pathways controlling urinary bladder volume reflexes.
The report 'P2X Purinoceptor 3 - Pipeline Review, H1 2020' outlays comprehensive information on the P2X Purinoceptor 3 (P2RX3) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies/Universities.
It also reviews key players involved in P2X Purinoceptor 3 (P2RX3) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase III, Phase II, Preclinical and Discovery stages are 1, 4, 5 and 2 respectively. Similarly, the universities portfolio in Preclinical stages comprises 1 molecule, respectively. Report covers products from therapy areas Central Nervous System, Respiratory, Dermatology, Genito Urinary System And Sex Hormones, Ophthalmology and Women's Health which include indications Chronic Cough, Pain, Neuropathic Pain (Neuralgia), Cough, Inflammatory Pain, Pruritus, Visceral Pain, Alzheimer's Disease, Endometriosis, Insomnia, Obstructive Sleep Apnea, Ocular Hypertension, Open-Angle Glaucoma, Overactive Bladder and Sleep Apnea.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the global therapeutic landscape for P2X Purinoceptor 3 (P2RX3)
- The report reviews P2X Purinoceptor 3 (P2RX3) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in P2X Purinoceptor 3 (P2RX3) targeted therapeutics and enlists all their major and minor projects
- The report assesses P2X Purinoceptor 3 (P2RX3) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to P2X Purinoceptor 3 (P2RX3) targeted therapeutics
Reasons to Buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for P2X Purinoceptor 3 (P2RX3)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding P2X Purinoceptor 3 (P2RX3) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Table of Contents
- Introduction
- Report Coverage
- P2X Purinoceptor 3 (P2RX3) - Overview
- P2X Purinoceptor 3 (P2RX3) - Therapeutics Development
- Products under Development by Stage of Development
- Products under Development by Therapy Area
- Products under Development by Indication
- Products under Development by Companies
- Products under Development by Universities/Institutes
- P2X Purinoceptor 3 (P2RX3) - Therapeutics Assessment
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- P2X Purinoceptor 3 (P2RX3) - Companies Involved in Therapeutics Development
- Asana BioSciences LLC
- Bayer AG
- Beijing Tide Pharmaceutical Co Ltd
- BELLUS Health Inc
- Integral Molecular Inc
- Merck & Co Inc
- Neurim Pharmaceuticals Ltd
- Ossianix Inc
- Pfizer Inc
- Shionogi & Co Ltd
- P2X Purinoceptor 3 (P2RX3) - Drug Profiles
- ASN-009 - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- BAY-1817080 - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- BLU-5937 - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- gefapixant citrate - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- Monoclonal Antibodies to Antagonize P2X3 Receptor for Pain - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- Monoclonal Antibody to Antagonize P2X2 and P2X3 for Visceral Pain - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- P2X Purinoceptor 3 (P2RX3) - Dormant Products
- P2X Purinoceptor 3 (P2RX3) - Discontinued Products
- P2X Purinoceptor 3 (P2RX3) - Product Development Milestones
- Featured News & Press Releases
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact Us
- Disclaimer
List of Tables
- Number of Products under Development by Stage of Development, H1 2020
- Number of Products under Development by Therapy Areas, H1 2020
- Number of Products under Development by Indication, H1 2020
- Number of Products under Development by Companies, H1 2020
- Products under Development by Companies, H1 2020
- Products under Development by Companies, H1 2020 (Contd..1), H1 2020
- Number of Products under Investigation by Universities/Institutes, H1 2020
- Products under Investigation by Universities/Institutes, H1 2020
- Number of Products by Stage and Mechanism of Actions, H1 2020
- Number of Products by Stage and Route of Administration, H1 2020
- Number of Products by Stage and Molecule Type, H1 2020
- Pipeline by Asana BioSciences LLC, H1 2020
- Pipeline by Bayer AG, H1 2020
- Pipeline by Beijing Tide Pharmaceutical Co Ltd, H1 2020
- Pipeline by BELLUS Health Inc, H1 2020
- Pipeline by Integral Molecular Inc, H1 2020
- Pipeline by Merck & Co Inc, H1 2020
- Pipeline by Neurim Pharmaceuticals Ltd, H1 2020
- Pipeline by Ossianix Inc, H1 2020
- Pipeline by Pfizer Inc, H1 2020
- Pipeline by Shionogi & Co Ltd, H1 2020
- Dormant Products, H1 2020
- Dormant Products, H1 2020 (Contd..1), H1 2020
- Discontinued Products, H1 2020
List of Figures
- Number of Products under Development by Stage of Development, H1 2020
- Number of Products under Development by Therapy Areas, H1 2020
- Number of Products under Development by Top 10 Indications, H1 2020
- Number of Products by Stage and Mechanism of Actions, H1 2020
- Number of Products by Stage and Route of Administration, H1 2020
- Number of Products by Molecule Types, H1 2020
- Number of Products by Stage and Molecule Types, H1 2020
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Asana BioSciences LLC
- Bayer AG
- Beijing Tide Pharmaceutical Co Ltd
- BELLUS Health Inc
- Integral Molecular Inc
- Merck & Co Inc
- Neurim Pharmaceuticals Ltd
- Ossianix Inc
- Pfizer Inc
- Shionogi & Co Ltd
